Full text is available at the source.
Abstract
Tirzepatide may lead to more weight loss than selective GLP-1 receptor agonists.
- The rise in obesity prevalence highlights the need for effective therapies.
- Tirzepatide acts on receptors for the hormones GLP-1 and GIP, suggesting a dual mechanism for weight loss.
- CNS incretin receptors may play a role in regulating body weight, although their exact contributions remain unclear.
- Current evidence indicates that both activating and inhibiting GIP receptors can result in weight loss in preclinical studies.
- Recent advancements in incretin-based therapies could enhance weight loss strategies for obese individuals.
Simplified